These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31511186)

  • 41. Evaluating Frameworks That Provide Value Measures for Health Care Interventions.
    Mandelblatt JS; Ramsey SD; Lieu TA; Phelps CE
    Value Health; 2017 Feb; 20(2):185-192. PubMed ID: 28237193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.
    Lomas JRS
    Value Health; 2019 Aug; 22(8):898-905. PubMed ID: 31426931
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
    Angelis A; Kanavos P
    Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness league tables: valuable guidance for decision makers?
    Mauskopf J; Rutten F; Schonfeld W
    Pharmacoeconomics; 2003; 21(14):991-1000. PubMed ID: 13129413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?
    Jit M; Hutubessy R
    Appl Health Econ Health Policy; 2016 Jun; 14(3):245-52. PubMed ID: 26832145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decision-making frameworks and considerations for informing coverage decisions for healthcare interventions: a critical interpretive synthesis.
    Morgan RL; Kelley L; Guyatt GH; Johnson A; Lavis JN
    J Clin Epidemiol; 2018 Feb; 94():143-150. PubMed ID: 28988959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
    Wong CKH; Wu O; Cheung BMY
    Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
    Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
    BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patients Should Define Value in Health Care: A Conceptual Framework.
    Kamal RN; Lindsay SE; Eppler SL
    J Hand Surg Am; 2018 Nov; 43(11):1030-1034. PubMed ID: 29754755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using health economic models to help guide healthcare decisions.
    Charokopou M
    Curr Med Res Opin; 2016; 32(2):205-6. PubMed ID: 26473453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Measuring Efficiency at the Interface of Behavioral and Physical Health Care.
    Ramanuj PP; Scharf DM; Ferenchick E; Spaeth-Rublee B; Pincus HA
    J Ment Health Policy Econ; 2018 Jun; 21(2):79-86. PubMed ID: 29961047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic decision making in healthcare. A standard approach to discounting health outcomes.
    Hillman AL; Kim MS
    Pharmacoeconomics; 1995 Mar; 7(3):198-205. PubMed ID: 10155309
    [No Abstract]   [Full Text] [Related]  

  • 56. Economic aspects of clinical decision making: applications in patient care.
    Oster G
    Am J Hosp Pharm; 1988 Mar; 45(3):543-7. PubMed ID: 3130753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic evidence at the local level : options for making it more useful.
    van Gool K; Gallego G; Haas M; Viney R; Hall J; Ward R
    Pharmacoeconomics; 2007; 25(12):1055-62. PubMed ID: 18047389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decision-making by healthcare payers.
    Levine M; Taylor R; Ryan M; Sculpher M
    Respir Med; 2002 Aug; 96 Suppl C():S31-8. PubMed ID: 12199490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Health Economics Approach to US Value Frameworks: Serving the Needs of Decision Making.
    Norman R; Chalkidou K; Culyer AJ
    Value Health; 2018 Feb; 21(2):117-118. PubMed ID: 29477387
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.